Vir Biotechnology, Inc. (VIR)
After hours:
| Previous close | 10.66 |
| Open | 10.90 |
| Bid | 10.68 x 200 |
| Ask | 10.72 x 400 |
| Day's range | 10.58 - 11.00 |
| 52-week range | 7.61 - 14.27 |
| Volume | |
| Avg. volume | 1,169,540 |
| Market cap | 1.456B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.01 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.29 |
Business WireVir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
SAN FRANCISCO, July 18, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024.
Business WireVir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
SAN FRANCISCO, June 26, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the Company’s
Simply Wall St.Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
